IMPACT-HTA: Improved Methods and Actionable Tools for Enhancing Health Technology Assessment/description and explication of European Healthcare and Social Cost Database (EU HCSCD) to the general public

Development of the European Healthcare Cost Database (EU HCCD) for economic evaluation of health technologies/ poster made for ISPOR Europe 2019

Costs. IMPACT-HTA project/ Explanation of costing methodology and European Healthcare and Social Cost Database (EU HCSCD) in Course in Methodology of economic evaluation of medicines and healthcare technologies

The development of the European healthcare costs database in order to strengthen the use of evaluation of healthcare technologies: IMPACT-HTA project/ oral presentation made in VI Workshop EEconAES 2019

Adjusting costs for inflation in economic evaluation of healthcare/ poster presented in ISPOR Europe 2020

Description of day case costs and tariffs of cataract surgery from a sample of nine European countries. Analysis of data from European Healthcare and Social Cost Database (EU HCSCD)/ oral presentation made in II Workshop GestionAES 2020

Health does not have a price, but it does have a cost: differences in unit costs across Europe/ this event was part of European Researchers‘ Night (European Corner)

Are costs derived from Diagnosis-Related Groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database/ the presentation was made at VII Workshop EEconAES. Investigation in Economic Evaluation

Adjusting costs for economic evaluation of healthcare/the presentation was made at VII Workshop EEconAES. Investigation in Economic Evaluation

The role played by social costs in economic evaluations of rare disease interventions. Communication accepted on the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress/Communication presented as 'Poster' on ISPOR Europe 2019 congress. Economic evaluations carried out from a societal perspective are still scarce in the rare diseases. Perhaps, that could be the reason why the inclusion of societal costs has changed authors’ conclusions in just 1 study of 26 economic evaluations reviewed in this case study.

Assessing the effect of including social costs in economic evaluations: a systematic review of diabetes-related interventions / Communication presented as 'Poster' on Virtual ISPOR Europe 2020 congress. The results achieved in this case study stated that very few studies consider social costs in economic evaluations of diabetes-related interventions. However, we conclude that conclusions can be altered if they are included.

Considering the Societal Perspective in Economic Evaluations: A Systematic Review in the Case of Depression-Related Interventions. / Communication presented as 'Poster' on Virtual ISPOR Europe 2020 congress. Our results showed that societal perspective might alter the conclusions in cost-utility analyses when depression-related interventions are economic assessed. Hence, the relevance of the perspectives of costs analysis matters on depression field.

Social Costs in Multiple Sclerosis Economic Evaluations: Do Their Inclusion Change the Results and Conclusions? a Systematic Review / Communication presented as 'Poster' on Virtual ISPOR Europe 2020 congress. Compared with other diseases, social costs were more frequently included in economic evaluations of multiple sclerosis-related interventions. The inclusions of these costs have led to change results and conclusions in economic evaluations carried out in MS field.

The results on patient preferences were presented at the Virtual EuroQol Plenary Meeting 2020 which was organized by the EuroQol Research Foundation. The paper titled “To what extent do patient preferences differ from general population preferences?” was presented and discussed at that conference. The EuroQol Plenary meetings take place every year and invite all members of the EuroQol Group Association, an international network of multidisciplinary researchers, as well as external researchers that focus their work on EQ-5D instruments to present and discuss their work.

The results on the comparison of adult and adolescents’ preferences were presented at the Virtual EuroQol Plenary Meeting 2020 which was organized by the EuroQol Research Foundation. The paper titled “Comparison of adult and adolescent preferences towards EQ-5D-Y health states” was presented and discussed at that conference. The EuroQol Plenary meetings take place every year and invite all members of the EuroQol Group Association, an international network of multidisciplinary researchers, as well as external researchers that focus their work on EQ-5D instruments to present and discuss their work.

The preliminary results on the Spanish EQ-5D-Y value set were presented at the Virtual EuroQol Plenary Meeting 2020 which was organized by the EuroQol Research Foundation. The paper titled “Modelling Strategies for generating country-specific EQ-5D-Y value sets” was presented and discussed at that conference. The EuroQol Plenary meetings take place every year and invite all members of the EuroQol Group Association, an international network of multidisciplinary researchers, as well as external researchers that focus their work on EQ-5D instruments to present and discuss their work.

A short report and the video on the final Impact HTA Workshop was put on the website of the Department of Health Economics and Health Care Management at Bielefeld University to inform the interested public on current research activities. Link: https://www.uni-bielefeld.de/fakultaeten/gesundheitswissenschaften/ag/ag5/aktuelles/

A poster on the results on the Spanish EQ-5D-Y value set was involved in a workshop on valuing Youth health, held by the EuroQol Research Foundation in June 2021. At this workshop, current work and evidence on that topic was presented and recommendations for the future were discussed. A group of interested members of the EuroQol Group Association and experts in this research field were invited to participate.

A poster on the preliminary results on the German EQ-5D-Y value set was involved in a workshop on valuing Youth health, held by the EuroQol Research Foundation in June 2021. At this workshop, current work and evidence on that topic was presented and recommendations for the future were discussed. A group of interested members of the EuroQol Group Association and experts in this research field were invited to participate.

A short report on the final IMPACT HTA results was put on the website of the Institute for Economic Research of Slovenia to inform the interested public on the results of the project and research activities. Link: http://www.ier.si/files/IMPACT%20HTA%20brosura.pdf. The article published in PharmacoEconomics on Slovenian EQ-5D-Y value set was published on the website of the Institute for Economic Research of Slovenia to inform the interested public on the availability of Slovenian EQ-5D-Y values. Link: http://www.ier.si/menu-273.php

The article published in PharmacoEconomics on Slovenian EQ-5D-Y value set was published on the website of DOBA Faculty of Slovenia to inform the interested public on the availability of Slovenian EQ-5D-Y values. https://www.doba.si/novice/izjemen-dosezek-visokosolske-uciteljice-doba-fakultete

A final IMPACT HTA brochure with the results of the project was sent by email to all major stakeholders in Slovenia healthcare and long-term care (Health Insurance Institute of Slovenia, Ministry of Health, University Clinical Centres, National Institute for Public Health, Association of Institutional CARE OF Slovenia, Association of Community Care of Slovenia

European Public Health Conference. Can we rely on non-randomised studies as input for health economic decision-making? Findings from a meta-epidemiological review and evidence-based recommendations.

ATHEA conference. Agreement of treatment effects in randomised vs. non-randomised studies: preliminary findings from a meta-epidemiological study.

NICE Technical Forum: Agreement of treatment effects in randomised vs. non-randomised studies: findings from a large-scale meta-epidemiological study.

IMPACT HTA WP6 workshop on the use of non-randomised evidence for comparative effectiveness estimation.

LSE Market Access Academy: Value assessment, HTA and MCDA (module 4)

DIA Middle East Regulatory Conference (MERC): HTA in the Middle East: Where can we invest and where can we build our capabilities?

ISPOR 2019 – HTA Roundtable: IMPACT HTA project presentation

14th Scientific Re-union on Health Technology Assessment from a societal perspective: EU cooperation in HTA: Failing, flawed or fair?

2nd HTA Conference: Reflections on HTA in Greece and ways forward

Dubai International Pharmaceuticals and Technologies Conference (DUPHAT) 2020: Multi-Criteria Decision Analysis for Health Technology Assessment: Which agenda to address methodological challenges?

HTAi conference 2020: On value frameworks and value assessment

Politicas de medicamentos y regulación de precios II: A course on value assessment and risk mitigation: multi-criteria decision analysis and risk sharing

Emirates Health Economics Society – Inauguration event: Towards a holistic approach to Health Technonlogy Assessment: From horizon Scanning to funding decisions

LSE Departmental seminar: Algorithms and heuristics of health technology assessments: A post hoc analysis of factors associated with funding decisions for new drugs across 8 OECD countries

3rd HTA Conference: The future of HTA relies on EU Member State cooperation

EUnetHTA Forum 2021: Presentation of the IMPACT HTA project and its achievements

Catholic University of the Sacred Heart: Algorithms and heuristics of health technology assessments: A post hoc analysis of factors associated with funding decisions for new drugs across 8 OECD countries

HTAi conference 2021: Applying co-creation process for development and consensus-building in comprehensive genomic profiling and next generation sequencing value assessment framework in Europe

ECPM Continuing Education Series – Integrated product development, healthcare marketplace and marketing: Health Technology Assessment

LSE Market Access Academy: Value assessment, HTA and MCDA (module 4)

Combining Web-Delphi with Decision Conferencing within a Collaborative Value Modelling frame: Case Studies

ORAHS2019 Conference: A multicriteria framework to assist HTA agencies on the evaluation of new drugs on a common basis.

Euro PhD summer school ‘Operational Research for Value-based Health Care’ 

International Decision Conferencing Forum

ORAHS2020 Conference: Designing Delphi knowledge construction processes to enable OR behavioural research and extend stakeholders’ analyses in health settings.

8th Conference of the Portuguese Association of Hospital Administrator “Innovate and lead under uncertainty”, “Operational Research in health care: which role for improving hospital management?”, Workshop in session: “E-LEARNING: Health service data simulation and predictive results”.

JointHealth: Digital Health Solutions Spring Welcome Seminars (Health Cluster Portugal and EIT Health): Operational Research and Decision Support Tools in Health Care: Which role for improving hospital management?

ORAHS2021 Conference: Designing and testing the IMPACT HTA socio-technical framework to assist HTA agencies in the multicriteria evaluation of new medicines on a common basis.

EURO2021 Conference: Designing and testing the IMPACT HTA socio-technical framework to assist HTA agencies in the multicriteria evaluation of new medicines on a common basis.

Italian Society of HTA (SIHTA)

Italia Longeva (National Association for Aging and Active Longevity)

iHEA: Predicting Health Utilities from Patient-Reported Outcome Measures (PROMs) in Rare Diseases: a systematic review and quality appraisal of ‘mapping’ studies

AIES: Predicting health utilities from PROMs in rare diseases: a systematic review of mapping studies

DIA ATMPs workshop: RWE for decisions about highly innovative technologies

ISPOR Europe 2019: Predicting health utilities from patient reported outcome measures in rare diseases: a systematic review of mapping studies

World Orphan Drug Conference Europe 2019: RWE and Early Dialogues for HTA of rare disease treatment

NICE Methods Review: Presentation of results to NICE Executive team

ECRD 2020: Do we need special processes to appraisal rare disease treatments?

DIA ATMPs workshop: Resolving HTA/Payer uncertainties with real-world evidence (RWE)

PSI 2020: RWE for HTA of highly innovative technologies

Orphanet newsletter to announce the publication of one peer review paper and our partnerships with them on Orphanet hosting WP10 IMPACT-HTA country vignettes of appraisal processes for rare disease treatments

HTAi 2020: Do we need special processes to appraise rare disease treatments?

ODRD Conference 2020: Appraising orphan drugs – how should we determine value?

World Orphan Drug Conference Europe 2020: Special processes to appraise rare disease treatments – developing feasible, consistent approaches

ISPOR Europe 2020: HTA need special approaches for patient reported outcomes in rare diseases?

ISPOR Europe 2020: Using PROMs in HTA for rare diseases

Association of British Pharmaceutical Industries, Scotland: Presentation on OBMEA and draft tools

Webinar #1: Special processes to appraise rare disease treatments – developing feasible, consistent approaches

Webinar #2: Outcomes-Based Managed Entry Agreements for Rare Disease Treatments

Webinar #3: Better use of Patient Reported Outcome Measures and Health State Utility Values in appraisal of Rare Disease Treatments

Webinar #4: Appraisal Framework suitable for Rare Disease Treatments

HTA conference - The role of HTA in the era of radical changes & disruptive innovation (Greece): Do we need special processes to appraisal rare disease treatments?

RWE4Decisions discussion with DG Santé: Sharing of OBMEA findings

Scottish Government: Presentation on OBMEA tools

OECD Expert Group on Pharmaceuticals and Medical Devices: Presentation on OBMEA tools and links to OECD work

CADTH scientific team: Discussion of OBMEA tools and granting of permission to use in new RWE processes

SMC Leaders: Confidential feedback on ethnographic observations

Many LinkedIn and twitter posts relating to WP10 presentations from the WP10 Principal Inverstigators’ accounts

HTAi 2021: Innovating HTA to support novel interventions for rare diseases

HTAi 2021: Using OBMEA to develop evidence for RDTs

HTAi 2021: Patient group submission template for re-appraisal after OBMEA

Canadian Organisation for Rare Diseases: Presentation of Appraisal Framework to inform Canadian development of rare disease policy

ISPOR Europe 2019: Annual cost of patients undergoing a total knee replacement in France

ISPOR Europe 2019: Budget impact analysis of triple therapy after failure of methotrexate for the treatment of rheumatoid arthritis in France

A technical workshop with stakeholders was organized. It gathered 16 French decision-makers, including members from the French social security, from the drug pricing committee (CEPS), the HAS Economics and Public Health Assessment Committee (CEESP) and researchers from economics and public health research institutes.

All WPs’ outputs are hosted on the IMPACT HTA website (freely accessible) for 5 years following the end of the project

ISPOR 2019 - HTA Roundtable 2019: Presenting IMPACT HTA’s objectives and WPs

EUnetHTA Bulletin: brief description of IMPACT HTA, its objectives, WPs and expected impacts

IMPACT HTA Final workshop

IMPACT HTA - Improved methods and actionable tools for enhancing HTA. Published on the project website and disseminated through social media

LSE Health newsletter to announce the conclusion of IMPACT HTA and the publication of the project report and workshop material.

LinkedIn and twitter posts from LSE Health Policy and MTRG accounts to disseminate news about events (final workshop, meetings, etc) and reports and outputs